| 1. |
|
|
| 2. |
- Berggren, Christian, 1950-, et al.
(författare)
-
Projekt utan partnerskap : om kunder konsulter och leverantörer i stora engångsprojekt
- 2001. - 1
-
Ingår i: Projekt: Organisation för målorientering och lärande. - Lund : Studentlitteratur. - 9144012438 - 9789144012438 ; , s. 202-219
-
Bokkapitel (övrigt vetenskapligt/konstnärligt)abstract
- Svenska industriföretag, tjänsteföretag och offentliga organisationer väljer i allt högre utsträckning att bedriva verksamhet i projektform. Projektet som arbetsform har gått från att ha varit något av en undantagslösning för unika insatser till att idag framstå som en ”grundbult” i sättet att organisera stora delar av verksamheten inom företag och organisationer. Därmed har också behovet av kunskaper om projektstyrning och projektorganisation ökat dramatiskt. I denna bok behandlas ledning, organisering och lärande i olika typer av projekt. Genom att boken tydligt tar sin utgångspunkt i konkreta fallbeskrivningar och kopplar dessa till aktuell organisations- och projektforskning, lämpar den sig som lärobok på projekt- och organisationskurser inom ekonom-, ingenjörs-, civilingenjörs- och systemvetarutbildningar vid universitet och högskolor. Den är också väl lämpad att användas som kursbok i företagsintern vidareutbildning, och på universitetens externa kurser och ledarskapsprogram. Boken är även intressant för var och en som på egen hand vill fundera över projektorganisationens för- och nackdelar.
|
|
| 3. |
- Munch, Marie W., et al.
(författare)
-
Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia The COVID STEROID 2 Randomized Trial
- 2021
-
Ingår i: Journal of the American Medical Association (JAMA). - : AMER MEDICAL ASSOC. - 0098-7484 .- 1538-3598. ; 326:18, s. 1807-1817
-
Tidskriftsartikel (refereegranskat)abstract
- Question What is the effect of 12 mg vs 6 mg of dexamethasone on the number of days alive without life support at 28 days in patients with COVID-19 and severe hypoxemia? Findings In this randomized trial that included 1000 patients with COVID-19 and severe hypoxemia, treatment with 12 mg/d of dexamethasone resulted in 22.0 days alive without life support at 28 days compared with 20.5 days in those receiving 6 mg/d of dexamethasone. This difference was not statistically significant. Meaning Compared with 6 mg of dexamethasone, 12 mg of dexamethasone did not statistically significantly reduce the number of days alive without life support at 28 days. This multicenter randomized clinical trial compares the effects of 12 mg/d vs 6 mg/d of dexamethasone in patients with COVID-19 and severe hypoxemia. IMPORTANCE A daily dose with 6 mg of dexamethasone is recommended for up to 10 days in patients with severe and critical COVID-19, but a higher dose may benefit those with more severe disease. OBJECTIVE To assess the effects of 12 mg/d vs 6 mg/d of dexamethasone in patients with COVID-19 and severe hypoxemia. DESIGN, SETTING, AND PARTICIPANTS A multicenter, randomized clinical trial was conducted between August 2020 and May 2021 at 26 hospitals in Europe and India and included 1000 adults with confirmed COVID-19 requiring at least 10 L/min of oxygen or mechanical ventilation. End of 90-day follow-up was on August 19, 2021. INTERVENTIONS Patients were randomized 1:1 to 12 mg/d of intravenous dexamethasone (n = 503) or 6 mg/d of intravenous dexamethasone (n = 497) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was the number of days alive without life support (invasive mechanical ventilation, circulatory support, or kidney replacement therapy) at 28 days and was adjusted for stratification variables. Of the 8 prespecified secondary outcomes, 5 are included in this analysis (the number of days alive without life support at 90 days, the number of days alive out of the hospital at 90 days, mortality at 28 days and at 90 days, and >= 1 serious adverse reactions at 28 days). RESULTS Of the 1000 randomized patients, 982 were included (median age, 65 [IQR, 55-73] years; 305 [31%] women) and primary outcome data were available for 971 (491 in the 12 mg of dexamethasone group and 480 in the 6 mg of dexamethasone group). The median number of days alive without life support was 22.0 days (IQR, 6.0-28.0 days) in the 12 mg of dexamethasone group and 20.5 days (IQR, 4.0-28.0 days) in the 6 mg of dexamethasone group (adjusted mean difference, 1.3 days [95% CI, 0-2.6 days]; P = .07). Mortality at 28 days was 27.1% in the 12 mg of dexamethasone group vs 32.3% in the 6 mg of dexamethasone group (adjusted relative risk, 0.86 [99% CI, 0.68-1.08]). Mortality at 90 days was 32.0% in the 12 mg of dexamethasone group vs 37.7% in the 6 mg of dexamethasone group (adjusted relative risk, 0.87 [99% CI, 0.70-1.07]). Serious adverse reactions, including septic shock and invasive fungal infections, occurred in 11.3% in the 12 mg of dexamethasone group vs 13.4% in the 6 mg of dexamethasone group (adjusted relative risk, 0.83 [99% CI, 0.54-1.29]). CONCLUSIONS AND RELEVANCE Among patients with COVID-19 and severe hypoxemia, 12 mg/d of dexamethasone compared with 6 mg/d of dexamethasone did not result in statistically significantly more days alive without life support at 28 days. However, the trial may have been underpowered to identify a significant difference.
|
|
| 4. |
- Sakao, Tomohiko, et al.
(författare)
-
Research on Services in the Manufacturing Industry based on a Holistic Viewpoint and Interdisciplinary Approach
- 2011
-
Ingår i: Functional thinking for value creation : proceedings of the 3rd CIRP International Conference on Industrial Product Service Systems. - Berlin, Heidelberg : Springer. - 9783642196881 ; , s. 27-32
-
Konferensbidrag (övrigt vetenskapligt/konstnärligt)abstract
- This paper begins by consolidating industrial challenges and research issues concerning Product/Service Systems obtained through various activities by the authors. Based on this, it points out the importance of the holistic view in further research in this area so that PSS providers do not fall into local optimization. The intent of this contribution to our research community includes shedding light on interesting issues that thus far have been relatively invisible and with narrower scope.
|
|
| 5. |
- Abdallah, J., et al.
(författare)
-
Masses, lifetimes and production rates of Xi(-) and Xi(+) at LEP 1
- 2006
-
Ingår i: Physics Letters B. - : Elsevier BV. - 0370-2693 .- 1873-2445. ; 639:3-4, s. 179-191
-
Tidskriftsartikel (refereegranskat)abstract
- Measurements of the Xi(-) and (Xi) over bar (+) masses, mass differences, lifetimes and lifetime differences are presented. The (Xi) over bar (+) sample used is much larger than those used previously for such measurements. In addition, the S production rates in Z -> b (b) over bar and Z -> q (q) over bar events are compared and the position xi* of the maximum of the distribution in Z -> q (q) over bar events is measured.
|
|
| 6. |
|
|
| 7. |
|
|
| 8. |
- Andersson, Hans, 1962-, et al.
(författare)
-
Individual Inventors in the R&D Factory
- 2007
-
Ingår i: Creativity and Innovation Management. - 0963-1690 .- 1467-8691. ; 16:4, s. 437-446
-
Tidskriftsartikel (refereegranskat)
|
|
| 9. |
|
|
| 10. |
|
|
